All Global articles – Page 107
-
White papersSo How About that Vaccine?
How close is a vaccine? Who will make money? What’s the impact to other health care sectors? Alexandra Hillier, Ben Eaton & Akan Oton join the Investment Institute and discuss public and private markets on what keeps us up at night (and home much of the day).
-
White papersWhere to next? - Embracing global real estate in the era of COVID-19
Real estate is an important part of any multi-asset portfolio. Going global rather than sticking to the domestic market can be highly beneficial for investors, though they must consider strategy carefully and actively manage risk.
-
White papersHigh Yield: Bridging the Gap to a Post-COVID World
What lies ahead for high yield markets? Head of Global Public Fixed Income, Martin Horne weighs in on what the bifurcated asset price recovery, record issuance levels and falling default expectations imply for high yield markets in the months ahead.
-
White papersCity of Fear? Fear of the city? Urban life and COVID-19
Fear City: A Survival Guide for Visitors to New York City was distributed to arrivals at New York City’s airports in June 1975 by police unions in dispute with city leaders about cuts in emergency services. It warned them graphically of the dangers that lay in wait in an increasingly chaotic city being abandoned by both terrified residents and disinterested politicians.
-
White papersInvestment View - The New Age of Financial Repression
Given the surge in government and corporate debt, policy will inevitably focus on making this load sustainable: financial repression, spearheaded by central banks, is set to reach a whole new level.
-
White papersPositioning for a green recovery from COVID-19
The improving economics of renewable power generation and the rise of electric vehicles and green hydrogen mean it is increasingly possible to decouple economic growth and carbon emissions. We believe Asia should follow the EU’s plan for EUR 225 billion in (truly) green bonds.
-
White papersPolitics, economics and a pandemic: Equity markets under pressure
September saw profit-taking on equities amid investor concerns over COVID-19 as well as economic and political uncertainties. After rallying for five months, global equities fell. Further fiscal support measures are taking shape, but only slowly, leaving central banks to lobby for more haste.
-
White papersDisruptive technology in the COVID-19 era
Within the global economy, COVID-19 has acted as a formidable accelerator of trends driving disruptive technology. Valuations of information technology stocks have soared, raising questions about the extent of the rally. Guy Davies, chief investment officer for fundamental active equities, explains why this time may be different.
-
White papersYou asked, we answer
Our Global Views team attempts to answer some of the questions often asked by our clients.
-
White papersFixed income dynamics in the current monetary and fiscal landscape
The global economy rebounded quickly during the summer from the coronavirus pandemic. In this phase of recovery, central banks played a key role in the massive supply of credit to governments and companies. To tackle the health crisis, almost all governments implemented large-scale fiscal stimulus and support measures, including corporate loan guarantees. At the same time, major central banks increased their purchases of sovereign debt to levels never seen before, played a backstop role in the corporate debt market and provided cheap liquidity to banks (in the case of the ECB).
-
White papersContraction > recovery > late cycle: the cycle round trip is confirmed Advanced Investment Phazer: top-down assessment
The global recovery continues at different speeds and compositions at the regional level. Policies are pivotal in shaping the recovery trajectories, influencing market participants’ narratives and rebuilding confidence.
-
White papersGlobal Investment Views - October 2020
Back from holidays, investors are dealing with rising volatility in the equity markets and initial signs of a fall in the extreme market complacency over the last few months. After the summer overshoot, Big Tech stocks have seen a pullback and some tensions have also materialized in the US HY segment, while IG markets remained more or less flat in the last month.
-
White papersScenarios Around the “Not Quite Recovery”
We’ve come a long way since March, but there’s still a long road ahead. So far, the recovery is encouraging but the permanent damage to employment remains to be seen, as does the resilience of company balance sheets.
-
White papersThe low volatility anomaly in equity sectors – 10 years later!
A decade ago, BNP Paribas Asset Management launched the global low volatility equity strategy after undertaking proprietary research into the characteristics of low risk stocks.
-
White papersOn the Road to Japanification
Sentiment around monetary policy, fiscal policy and a host of other factors can swing markets, but can anything return us to sustained growth and inflation?
-
White papersThe Biggest Threat to the Global Recovery Lies Beneath This Dome
Rising acrimony at the U.S. Capital around the Supreme Court vacancy puts stimulus at risk and hurts long-term growth prospects.
-
White papersTech innovation: reaching all sectors
Companies across a range of industries are deploying innovative technologies to spark rapid growth, creating attractive investment opportunities
-
White papersShipping: a social industry making environmental strides
Transport assets remind us that, within ESG investing, “S” can be just as important as “E” and “G”, and focusing on the environment and governance at the expense of social aspects can be detrimental
-
White papersClimate change: asset managers join forces with the eco-warriors
The pandemic has persuaded some investors of the potential financial damage from global warming
-
White papersThe coronavirus and the race for a vaccine
Across the globe, scientists are hunting for an effective vaccine that will end Covid-19. In the sixth article in our pandemic series, Katie Frame looks at the response from the pharmaceutical sector and how we engage on this issue.
